Figure 6.

MG132 sensitizes TRAIL-resistant cells by inhibiting FBXL10 and activating c-Fos. (a) LNCaP cells were treated with 50 ng/ml TRAIL or/and 2 μM MG132 for 8 h and immunoblot was performed. (b) PC3TR cells were treated as shown in (a) and RT-PCR was performed. (c) LNCaP cells were treated with 50 ng/ml TRAIL and 2 μM MG132 for the times shown and immunoblot was performed. (d) PC3 and LNCaP cells transfected with pFBXL10 reporter plasmids and were treated as shown in a. Renilla luciferase was used as a positive control. Results are shown as the mean (bar) ± S.D. of at least three independent experiments. (e) PC3TR cells treated cells as shown in a were subjected to ChIP assay using a FBXL10 antibody or IgG. (f) Nuclear extracts from LNCaP cells treated as shown in a were incubated with FBXL10BS probe in the presence or absence of FBXL10 antibody. Arrows indicate the super-shifted FBXL10 protein–DNA complexes. All experiments were repeated independently at least three times with similar results